-->

Tech Seeker (TS)

La Jolla Pharmaceutical Company
Profile last edited on: 7/2/2013

a biopharmaceutical company, engages in the discovery and development of orally-active small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders
TS Type
N/A
Status
Year Founded
1989
Last Involved Year
2009

Key People / Management

  George F Tidmarsh -- President

Location Information

4365 Executive Drive Suite 1070
San Diego, CA 92122-1249
   858-207-4264
   www.ljpc.com

Public Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The company?s products include GCS-100, a Phase-1/2 clinical trial drug used for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome. In addition, the company is developing LJPC-101, a subcutaneous formulation of GCS-100; LJPC-201, an oral galectin-3 inhibitor; and LJPC-301, a monoclonal antibody designed to neutralize galectin-3. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
4
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
OTC : LJPC
Received SBIR $$
No

SBIR firms in the news

There are no news available.